CUMBERLAND, R.I.--(BUSINESS WIRE)--Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced the presentation of a scientific poster summarizing the results of in vitro and pharmacokinetic studies for its tamper-resistant, extended-release oral oxycodone formulation (COL-003), which is the lead product candidate utilizing the Company’s DETERx™ technology. The poster, entitled, “Tamper-Resistant Properties and Bioavailability of a Novel, Multiparticulate, Extended-Release Formulation of Oxycodone for the Treatment of Moderate to Severe Pain”, will be presented at the American Academy of Pain Medicine’s 26th Annual Meeting, February 3-6, in San Antonio, Texas. The poster will be displayed and presented on February 3rd and 4th.
